- Home
- NRSN vs BOLD Comparison
NRSN vs BOLD Comparison
Compare NRSN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- BOLD
- Stock Information
- Founded
- NRSN 2017
- BOLD 2018
- Country
- NRSN Israel
- BOLD United States
- Employees
- NRSN N/A
- BOLD N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- NRSN Health Care
- BOLD
- Exchange
- NRSN Nasdaq
- BOLD Nasdaq
- Market Cap
- NRSN 31.1M
- BOLD 25.5M
- IPO Year
- NRSN 2021
- BOLD 2024
- Fundamental
- Price
- NRSN $1.22
- BOLD $1.30
- Analyst Decision
- NRSN Buy
- BOLD Buy
- Analyst Count
- NRSN 2
- BOLD 4
- Target Price
- NRSN $14.00
- BOLD $4.00
- AVG Volume (30 Days)
- NRSN 404.8K
- BOLD 138.1K
- Earning Date
- NRSN 09-17-2025
- BOLD 11-06-2025
- Dividend Yield
- NRSN N/A
- BOLD N/A
- EPS Growth
- NRSN N/A
- BOLD N/A
- EPS
- NRSN N/A
- BOLD N/A
- Revenue
- NRSN N/A
- BOLD N/A
- Revenue This Year
- NRSN N/A
- BOLD N/A
- Revenue Next Year
- NRSN N/A
- BOLD N/A
- P/E Ratio
- NRSN N/A
- BOLD N/A
- Revenue Growth
- NRSN N/A
- BOLD N/A
- 52 Week Low
- NRSN $0.80
- BOLD $1.00
- 52 Week High
- NRSN $2.60
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- NRSN 44.56
- BOLD 66.93
- Support Level
- NRSN $1.12
- BOLD $1.10
- Resistance Level
- NRSN $1.26
- BOLD $1.26
- Average True Range (ATR)
- NRSN 0.06
- BOLD 0.04
- MACD
- NRSN 0.01
- BOLD 0.01
- Stochastic Oscillator
- NRSN 36.87
- BOLD 87.50
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.